We are live on ! Find out more
GTBP icon

GT Biopharma

31 hedge funds and large institutions have $1.11M invested in GT Biopharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

11% more funds holding

Funds holding: 28 → 31 (+3)

7.82% less ownership

Funds ownership: 16.69% → 8.87% (-7.8%)

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

92% less capital inflows, than outflows

Capital inflows: $106K | Capital outflows: $1.29M

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GTBP Hedge Fund Activity: Q2 2023 in Review

31 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2023, worth a combined $1.11M — down 64% from $3.05M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GTBP positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.

The largest buyer was Bank of Montreal, adding an estimated $48.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.21M sold.

  • 31 institutional investors held GT Biopharma (GTBP) as of Q2 2023, up from 28 in Q1 2023.
  • Funds reported $1.11M of GT Biopharma stock for Q2 2023, down 64% quarter-over-quarter.
  • 5 funds opened new GT Biopharma positions in Q2 2023 and 2 closed out, a net change of +3 holders.
  • The largest GT Biopharma buyer in Q2 2023 was Bank of Montreal, an estimated $48.2K added.
  • The largest GT Biopharma seller in Q2 2023 was Armistice Capital, an estimated $1.21M sold.

Based on aggregated 13F filings for Q2 2023.